GSK’s COPD Drug Gets A New Name (Breo) But May Face Familiar Challenges At FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The respiratory drug’s fate is uncertain given its mixed Phase III trial results; in two pivotal studies Breo, formerly Relovair, failed to demonstrate superiority to GSK’s Advair.
You may also be interested in...
Further Mixed Results For GSK/Theravance’s Relovair Have Investors Holding Breath
GSK and Theravance released preliminary results of two Phase III studies for their COPD drug Relovair that could serve to help differentiate the drug from Advair.
Relovair Data Raises Respiratory Stakes For GSK And Theravance
Mixed Phase III data results on GSK/Theravance’s once-daily follow-up to Advair raises the regulatory and commercial stakes for the drug, a crucial pipeline product for both companies
Patent Process Reforms Proposed By US PTO Could Be ‘Quite Burdensome’ For Applicants
Patent office requests comments on its proposed initiatives, with continuation patents appearing a particular target. PTO asks if filing a terminal disclaimer for patents that are a variation of each other should be an admission they are obvious.